摘要
目的观察伊立替康联合顺铂治疗进展期食管鳞癌的疗效。方法 2007-05-20—2009-05-20共入组进展期食管鳞癌患者46例,采用伊立替康75 mg/m2,持续静脉滴注90 min,第1、8天;顺铂25 mg/m2,静脉滴注,第1～3天;21 d为1个周期;至少完成2个周期化疗者方可评价疗效。结果本组46例患者共完成188个化疗周期,在可评价疗效的45例患者中,完全缓解5例,部分缓解16例,稳定13例,进展11例,有效率为46.7%(21/45),疾病控制率为75.6%(34/45);1年生存率为20.0%(9/45),中位疾病进展时间为5.0个月〔95%CI(3.9,6.1)〕,中位生存时间为9.0个月〔95%CI(8.3,9.7)〕;化疗主要毒副作用为腹泻、脱发、恶心、血小板减少、粒细胞减少、呕吐等。结论伊立替康联合顺铂治疗进展期食管鳞癌疗效确切,安全性及患者依从性好,可作为进展期食管鳞癌的治疗方案。
Objective To investigate the efficacy and toxicity of irinotecan combined with cisplatin in treatment for pa- tients with advanced esophageal squamous cell carcinoma. Methods A total of 46 patients with advanced esophageal squmous cell carcinoma admitted from May 2007 to May 2009 were given irinotecan, 75 mg/m2 , iv gtt for 90 rain, on days 1, 8, and cisplatin 25 mgc/m2, iv gtt, on day 1 ~ 3. One cycle lasted 21 d. The effect was evaluated at least after 2 cycles. Results This group of patients completed altogether 188 cycles. In 45 patients whose effects were evaluable, 5 remitted completely, 16 partly, 13 had stable condition, 11 had progression, the effective rate was 46. 7% （21/45）, disease control rate was 75.6% （34/45） , 1 -year survival rate was 20. 0% （9/45） , median progressive time was 5.0 months [95%CI （3.9, 6. 1 ） ] , me- dian survival time was 9. 0 months [95% CI （8.3, 9. 7） 1. The main toxicity of chemotherapy were diarrhea, hair loss, nause- a, thromboeytopenia, neutropenia, vomiting. Conclusion The effectiveness of irinotecan combined with cisplatin treating ad- vanced esophageal squmous cell carcinoma is definite with good safety and patients＇compliance, which can be used as treatment programs for advanced esophageal squamous cell carcinoma.
出处
《中国全科医学》
CAS
CSCD
北大核心
2013年第14期1669-1671,共3页
Chinese General Practice
关键词
伊立替康
顺铂
食管肿瘤
抗肿瘤联合化疗方案
Irinotecan
Ciaplatin
Esophageal neoplasms
Antineoplastic combined chemotherapy protocols
